Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer

Inclusion Criteria: * Participant is able to provide signed informed consent * Participant is female and ≥ 18 years of age or older if required by local laws or regulations * Participant has histologically or cytologically confirmed adenocarcinoma of the breast that is now metastatic or locally-recurrent and inoperable with curative intent. Every effort should be made to make paraffin-embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis * Participant has measurable and/or non-measurable disease * Participants' primary and/or metastatic tumor is human epidermal growth factor receptor 2 (HER2)-negative by fluorescence in-situ hybridization (FISH) or chromogenic in-situ hybridization (CISH) or 0, 1+ overexpression by immunohistochemistry (IHC) * Participant has not received prior chemotherapy for metastatic or locally-recurrent and inoperable breast cancer * Participant completed (neo) adjuvant taxane therapy at least 6 months prior to randomization * Participant completed (neo) adjuvant biologic therapy at least 6 weeks prior to randomization * Participant completed all prior radiotherapy with curative intent ≥ 3 weeks prior to randomization * Participant may have received prior hormonal therapy for breast cancer in the (neo) adjuvant and/or the metastatic setting ≥ 2 weeks prior to randomization * Participant's left ventricular ejection fraction is within normal institutional ranges * Participant has resolution to g…